What is ELEVIDYS (delandistrogene moxeparvovec-rokl)? ELEVIDYS is a prescription gene therapy used to treat ambulatory individuals at least 4 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene.

ELEVIDYS is an adeno-associated virus vector-based gene therapy indicated in individuals at least 4 years of age: during administration and for at least 3 hours after end of infusion. • For the treatment of Duchenne muscular dystrophy (DMD) in

ELEVIDYS is a prescription gene therapy used to treat ambulatory individuals at least 4 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene. ELEVIDYS is approved under accelerated approval for non-ambulatory patients at least 4 years old with DMD who have a confirmed mutation in the DMD gene ...

ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose gene transfer therapy intravenous for infusiondesigned to address the underlying cause of Duchenne muscular dystrophy through the targeted

ELEVIDYS is a prescription gene therapy used to treat ambulatory individuals with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene.

ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV) -based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the

ELEVIDYS is a prescription gene therapy used to treat ambulatory children aged 4 through 5 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene. ELEVIDYS was approved under accelerated approval.

ELEVIDYS es una terapia genética de venta con receta que se usa para tratar a pacientes ambulatorios de al menos 4 años de edad con distrofia muscular de Duchenne (DMD) que tienen una mutación confirmada en el gen DMD .

ELEVIDYS está indicado para el tratamiento de la distrofia muscular de Duchenne (DMD) en personas de al menos 4 años de edad: • Para pacientes que son ambulatorios y tienen una mutación confirmada en el gen DMD

ELEVIDYS is an adeno-associated virus vector-based gene therapy indicated for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. This indication is approved under accelerated approval based on expression of ELEVIDYS micro-